First randomised evidence for benefit from adding a tyrosine kinase inhibitor in acute myeloid leukaemia

Children with rare leukaemia have better-than-expected outcomes after tailored treatment

Chemo-free treatment approach demonstrates positive responses in leukaemia patients

Compound improves survival in aggressive acute myeloid leukaemia with manageable added toxicity in phase III trial

Blocking PD-1 activity could be safe and effective in classical Hodgkin lymphoma

Nivolumab shows early promise in Hodgkin lymphoma

Blinatumomab demonstrates significant clinical activity in residual ALL

New immunotherapy compound effective, safe in ALL patients with minimal residual disease

T cell therapy leading to prolonged remission for children with aggressive leukaemia

Checkpoint inhibitors show safety and efficacy in Hodgkin lymphoma

ASH 2014: Expert discussion on the latest in AML

Pembrolizumab may bring hope for patients with Hodgkin lymphoma